Supernus Announces Resignation of Board Member
ROCKVILLE, Md., Dec. 24, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that
Michael Bigham, a General Partner at Abingworth has resigned from the
company's board of directors, effective December 23, 2013.
"Abingworth remains a significant shareholder in Supernus but as a matter of
general practice we limit the time we spend on the boards of our portfolio
companies once they have become public companies," said Michael Bigham. Jack
Khattar, Chief Executive Officer, President and Director of Supernus commented
that, "Since joining the Supernus Board of Directors in 2006, Michael Bigham
has been a great contributor providing the Board with great insight and
judgment based on his vast experience in the healthcare industry. We will miss
him, and are grateful for his service."
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR^® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack Khattar, President & CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.